Multispecific yet truly natural antibodies

Multispecific yet truly natural antibodies

Multispecific yet truly natural antibodies

Light Chain Bioscience brings to life the research and development of multi-specific antibodies that rely on their light chains for function
Who we are
Who we are

Our antibody development roots go deep

Our antibody development roots go deep

Our focus
Our focus

Multispecific yet natural

Multispecific yet natural

CD47 Dual targeting
CD47 Dual targeting

Safe and selective blockade of CD47 on tumors

Safe and selective blockade of CD47 on tumors

Looking into the future
Looking into the future

Beyond bispecific antibodies

Beyond bispecific antibodies

previous arrow
next arrow
Exclusive interview lead by PharmaBoardroom

Exclusive interview lead by PharmaBoardroom


Nicolas Fischer, CEO introduces Light Chain Bioscience | Novimmune SA.

GENEVA, SWITZERLAND/ SWITZERLAND BIOTECH - PHARMA BOARDROOM/ MARCH 16, 2021 /

“????????????ℎ???? ????ℎ???????????? ???????????????????????????????????????? ???????????????????????????? ???????? ????ℎ???? ???????????????????????????????????????????????????????? ???????????? ???????????????????????????????????????????? ???????? ???????????????????????????????????????? ???????????? ???????????????????????????????????????????????????? ???????????????????????????????????????? ???????????????????? ???????????? ???????????????????????????????????????????? ???????????????????????? ???????????????????????? ????????????????????-???????????????????????? ????????????????™.”

 Read full [ARTICLE] :

exclusive interview lead by pharmaboardroom

  

PharmaBoardroom Limited
International House
24 Holborn Viaduct
London, EC1A 2BN, UK

+44 20 7867 37 17
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

New publication in Frontiers

Targeting CEACAM5-positive solid tumors using NILK-2401, a novel CEACAM5xCD47 κλ bispecific antibody


Read more

LinkedIn